Fig. 7: The positive correlations of ANXA6 and EGFR and exosomal ANXA6 are less enriched in gemcitabine-sensitive patients. | Cell Death & Disease

Fig. 7: The positive correlations of ANXA6 and EGFR and exosomal ANXA6 are less enriched in gemcitabine-sensitive patients.

From: Exosomal annexin A6 induces gemcitabine resistance by inhibiting ubiquitination and degradation of EGFR in triple-negative breast cancer

Fig. 7

A Scatter plot of ANXA6 and EGFR protein levels as assessed via immunohistochemistry using a tissue microarray constructed by samples from 81 patients with triple-negative breast cancer. The baseline characteristics of the 81 patients are shown in Supplementary Table 1. B Representative images of ANXA6 and EGFR immunohistochemistry in primary triple-negative breast cancer tissue. Low ANXA6 protein expression in a tumor with low EGFR protein expression (case 1) and high ANXA6 protein expression in a tumor with high EGFR protein expression (case 2). C ELISA revealed that the baseline levels of exosomal ANXA6 isolated from the serum of patients with triple-negative breast cancer were lower in sensitive patients with the best response of complete or partial responses (n = 14) than in those with stable or progressive disease (n = 7). The tumor response was assessed at every two or three cycles. The baseline characteristics of 21 patients are shown in Supplementary Table 2.

Back to article page